Unknown

Dataset Information

0

Modulation of microglial phenotypes by dexmedetomidine through TREM2 reduces neuroinflammation in heatstroke.


ABSTRACT: No FDA approved pharmacological therapy is available to reduce neuroinflammation following heatstroke. Previous studies have indicated that dexmedetomidine (DEX) could protect against inflammation and brain injury in various inflammation-associated diseases. However, no one has tested whether DEX has neuro-protective effects in heatstroke. In this study, we focused on microglial phenotypic modulation to investigate the mechanisms underlying the anti-inflammatory effects of DEX in vivo and in vitro. We found that DEX treatment reduced the expression of CD68, iNOS, TNF-α, and IL-1β, and increased the expression of CD206, Arg1, IL-10 and TGF-β in microglia, ameliorating heatstroke induced neuroinflammation and brain injury in mice. TREM2, whose neuro-protective function has been validated by genetic studies in Alzheimer's disease and Nasu-Hakola disease, was significantly promoted by DEX in the microglia. TREM2 esiRNA reversed the DEX-induced activation of PI3K/Akt signalling. Overall these findings indicated that DEX may serve, as a potential therapeutic approach to ameliorate heatstroke induced neuroinflammation and brain injury via TREM2 by activating PI3K/Akt signalling.

SUBMITTER: Li P 

PROVIDER: S-EPMC8233427 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC10434858 | biostudies-literature
| S-EPMC11363852 | biostudies-literature
| S-EPMC7033501 | biostudies-literature
| S-EPMC8026688 | biostudies-literature
| S-EPMC6433910 | biostudies-literature
| S-EPMC7442838 | biostudies-literature
2022-10-08 | GSE210897 | GEO
| S-EPMC4184669 | biostudies-literature
| S-EPMC5806703 | biostudies-literature
| S-EPMC7682066 | biostudies-literature